CERENOME, INC.

For the period ended Jun 30, 2026. Filed Aug 14, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 14, 2026

CNSY$0.68+19.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity/(Deficit

(UNAUDITED) (In thousands, except share data)

Convertible · Additional · Total
preferred stock · Common stock · Treasury Stock · paid-in · Accumulated · stockholders’
Shares · Amount · Shares · Amount · Shares · Amount · capital · deficit · (deficit)/equity
Balance at December 31, 2024	1,952	$	—	246,190		$	—		(10,337)		$	(500)		$	485,030		$	(493,479)		$	(8,949)
Stock-based compensation	—		—	—			—		—			—			148			—			148
Exercise of pre-funded warrants	—		—	261,429			1		—			—			(1)			—			—
Exercise of Series B Warrants from May 2024 PIPE	—		—	19,912			—		—			—			882			—			882
Exchange of warrants for notes payable	—		—	—			—		—			—			(3,694)			—			(3,694)
Issuance of common stock, pre-funded warrants and warrants for debt repayment	—		—	162,789			—		—			—			5,373			—			5,373
Net loss	—		—	—			—		—			—			—			(17,401)			(17,401)
Balance at March 31, 2025	1,952	$	—	690,320		$	1		(10,337)		$	(500)		$	487,738		$	(510,880)		$	(23,641)
Stock-based compensation	—		—	—			—		—			—			152			—			152
Exercise of March 2025 Series B Warrants	—		—	2,251,081			2		—			—			856			—			858
Exercise of pre-funded warrants	—		—	360,653			—		—			—			—			—			—
Cancellation of common stock	—		—	(12,000)			—		—			—			—			—			—
Issuance of common stock under Lincoln Park Purchase Agreement, net of issuance costs	—		—	407,480			1		—			—			2,745			—			2,746
Reclassification of 2025 Series B warrant liability to equity	—		—	—			—		—			—			10,967			—			10,967
Modification of warrants					—			—		—			6,801			—			6,801
Net income	—		—	—			—		—			—			—			5,151			5,151
Balance at June 30, 2025	1,952	$	—	3,697,534		$	4		(10,337)		$	(500)		$	509,259		$	(505,729)		$	3,034
Balance at December 31, 2025	1,952	$	—	5,557,371		$	6		(10,337)		$	(500)		$	520,355		$	(515,865)		$	3,996
Stock-based compensation	—		—	—			—		—			—			1,022			—			1,022
Cancellation of common stock	—		—	(272,821)			—		—			—			—			—			—
Issuance of common stock upon vesting of RSUs	—		—	8,867			—		—			—			—			—			—
Issuance of common stock upon public offering, net of issuance costs	—		—	1,578,947			1		—			—			13,888			—			13,889
Net loss	—		—	—			—		—			—			—			(6,946)			(6,946)
Balance at March 31, 2026	1,952	$	—	6,872,364		$	7		(10,337)		$	(500)		$	535,265		$	(522,811)		$	11,961
Stock-based compensation	—		—	—			—		—			—			830			—			830
Issuance of common stock upon vesting of RSUs	—		—	11,533			—		—			—			—			—			—
Issuance of common stock under Distribution Agreement, net of commissions and issuance costs	—		—	436,448			—		—			—			1,678			—			1,678
Net loss	—		—	—			—		—			—			—			(9,006)			(9,006)
Balance at June 30, 2026	1,952	$	—	7,320,345		$	7		(10,337)		$	(500)		$	537,773		$	(531,817)		$	5,463

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.